Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Warren Capell

Concepts (169)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Rivaroxaban
15
2024
254
2.520
Why?
Peripheral Arterial Disease
16
2024
458
2.080
Why?
Aspirin
13
2024
378
1.650
Why?
Factor Xa Inhibitors
8
2024
169
1.580
Why?
Lower Extremity
12
2024
404
1.510
Why?
Endovascular Procedures
5
2022
303
0.890
Why?
Platelet Aggregation Inhibitors
11
2024
439
0.820
Why?
Beneficence
1
2021
17
0.720
Why?
Thrombosis
2
2022
321
0.710
Why?
Hypertriglyceridemia
3
2006
39
0.710
Why?
Research Subjects
1
2021
42
0.700
Why?
Personal Autonomy
1
2021
48
0.690
Why?
Informed Consent
2
2021
174
0.690
Why?
Ischemia
6
2024
395
0.660
Why?
Patient Selection
2
2021
661
0.650
Why?
Outpatients
1
2021
366
0.570
Why?
Venous Thromboembolism
3
2023
274
0.450
Why?
Double-Blind Method
8
2024
1860
0.430
Why?
Drug Therapy, Combination
8
2024
1009
0.400
Why?
Lipoprotein Lipase
2
2010
58
0.390
Why?
Lipoproteins
4
2010
171
0.390
Why?
Hospitalization
2
2021
2071
0.380
Why?
Risk Assessment
1
2021
3256
0.370
Why?
Hypolipidemic Agents
3
2006
93
0.360
Why?
Fat Emulsions, Intravenous
1
2010
29
0.340
Why?
Coronary Artery Disease
2
2024
677
0.280
Why?
Hemorrhage
5
2023
644
0.280
Why?
Triglycerides
3
2010
524
0.260
Why?
Vascular Surgical Procedures
3
2024
293
0.240
Why?
Glucose
1
2010
983
0.240
Why?
Myocardial Infarction
2
2022
1014
0.230
Why?
Middle Aged
16
2024
30893
0.220
Why?
Male
22
2024
62883
0.220
Why?
Fatty Acids, Nonesterified
3
2010
159
0.210
Why?
Fenofibrate
1
2003
31
0.210
Why?
Fibrin Fibrinogen Degradation Products
1
2023
82
0.200
Why?
Antifibrinolytic Agents
1
2023
48
0.200
Why?
Treatment Outcome
9
2024
10163
0.200
Why?
Muscle, Skeletal
2
2010
1639
0.200
Why?
Multicenter Studies as Topic
2
2021
285
0.190
Why?
Humans
31
2024
128524
0.190
Why?
Female
20
2024
68127
0.190
Why?
Postoperative Complications
2
2024
2479
0.190
Why?
Blood Coagulation Disorders
1
2023
162
0.190
Why?
Drug-Eluting Stents
1
2021
64
0.180
Why?
Clinical Trials, Phase III as Topic
1
2021
90
0.180
Why?
Pragmatic Clinical Trials as Topic
1
2021
62
0.180
Why?
Placebos
1
2021
201
0.180
Why?
Paclitaxel
1
2021
214
0.170
Why?
Clinical Trials as Topic
3
2021
998
0.170
Why?
Follow-Up Studies
2
2021
4898
0.170
Why?
Extremities
1
2021
128
0.170
Why?
Vasodilation
1
2003
478
0.160
Why?
Cause of Death
1
2021
391
0.160
Why?
Subacute Care
1
2019
73
0.150
Why?
Brain Ischemia
1
2021
304
0.150
Why?
Nursing Homes
1
2019
151
0.140
Why?
Purinergic P2Y Receptor Antagonists
1
2018
66
0.140
Why?
Dose-Response Relationship, Drug
2
2021
1943
0.140
Why?
Aged
11
2024
21971
0.130
Why?
Health Services Research
1
2019
389
0.130
Why?
Hospital Mortality
1
2021
844
0.130
Why?
Lipoproteins, LDL
1
1996
126
0.130
Why?
Skilled Nursing Facilities
1
2017
128
0.120
Why?
Randomized Controlled Trials as Topic
1
2021
1358
0.120
Why?
Fibrinolytic Agents
1
2017
249
0.120
Why?
Insulin Resistance
3
2013
1166
0.120
Why?
Ethics, Research
1
2014
30
0.110
Why?
Consensus
1
2017
633
0.110
Why?
Anticoagulants
3
2023
613
0.110
Why?
Diabetes Mellitus, Type 2
2
2024
2430
0.110
Why?
Societies, Medical
1
2017
749
0.100
Why?
Disease Management
1
2017
588
0.100
Why?
Stroke
1
2021
1064
0.100
Why?
Caspase 1
1
2013
142
0.100
Why?
Cardiovascular Diseases
2
2021
2018
0.100
Why?
Interleukin-18
1
2013
237
0.090
Why?
Heparin
2
2023
240
0.090
Why?
Interleukin-1beta
1
2013
374
0.090
Why?
Research Design
1
2017
1038
0.090
Why?
Biomedical Research
1
2017
646
0.090
Why?
Arteries
2
2022
266
0.080
Why?
Transfection
2
2010
895
0.080
Why?
Dietary Fats
2
2010
301
0.080
Why?
Lactones
1
2010
58
0.080
Why?
Myoblasts
1
2010
80
0.080
Why?
Diet, Carbohydrate-Restricted
1
2010
32
0.080
Why?
Diet, Fat-Restricted
2
2010
79
0.080
Why?
Hypercholesterolemia
1
2010
101
0.080
Why?
Kaplan-Meier Estimate
2
2021
857
0.080
Why?
Obesity
2
2013
2860
0.070
Why?
Inflammation
2
2023
2664
0.070
Why?
Blotting, Western
1
2010
1168
0.070
Why?
Palliative Care
1
2014
716
0.070
Why?
Simvastatin
1
2006
55
0.070
Why?
Temperance
1
2005
13
0.060
Why?
Adult
5
2021
35315
0.060
Why?
Anticholesteremic Agents
1
2006
146
0.060
Why?
Cross-Over Studies
2
2006
513
0.060
Why?
Cell Line
1
2010
2731
0.060
Why?
Weight Loss
1
2010
723
0.060
Why?
Treatment Failure
1
2005
342
0.060
Why?
C-Reactive Protein
1
2006
396
0.060
Why?
Incidence
2
2021
2619
0.050
Why?
Heart Failure
1
2017
2150
0.050
Why?
Angiography
1
2024
192
0.050
Why?
Thromboplastin
1
2023
69
0.050
Why?
Forearm
1
2003
119
0.050
Why?
Vesicular Transport Proteins
1
2003
84
0.050
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2006
411
0.050
Why?
Metabolic Syndrome
1
2005
340
0.050
Why?
Numbers Needed To Treat
1
2021
7
0.050
Why?
Frailty
1
2024
149
0.050
Why?
Fasting
1
2003
263
0.050
Why?
Regional Blood Flow
1
2003
462
0.040
Why?
Postmenopause
1
2003
370
0.040
Why?
Antineoplastic Agents, Phytogenic
1
2021
186
0.040
Why?
Muscle, Smooth, Vascular
1
2003
417
0.040
Why?
Internationality
1
2020
148
0.040
Why?
Atherosclerosis
1
2024
405
0.040
Why?
Lipid Metabolism
1
2003
493
0.040
Why?
Nerve Tissue Proteins
1
2003
567
0.040
Why?
Alcohol Drinking
1
2005
749
0.040
Why?
Confidentiality
1
2019
67
0.040
Why?
Mice
3
2013
16579
0.040
Why?
Acute Disease
1
2021
968
0.040
Why?
Algorithms
1
2006
1616
0.040
Why?
Global Health
1
2021
326
0.040
Why?
Practice Guidelines as Topic
1
2006
1490
0.040
Why?
Proportional Hazards Models
1
2021
1208
0.040
Why?
Proteins
1
2003
936
0.030
Why?
Combined Modality Therapy
1
2020
1209
0.030
Why?
Membrane Proteins
1
2003
1108
0.030
Why?
Arteriosclerosis
1
1996
88
0.030
Why?
Cholesterol, LDL
2
2010
361
0.030
Why?
Patient Safety
1
2019
290
0.030
Why?
Risk Factors
2
2022
9727
0.030
Why?
Particle Size
1
1996
352
0.030
Why?
Reference Values
1
1996
780
0.030
Why?
Patient Transfer
1
2017
164
0.030
Why?
Disease Susceptibility
1
1996
334
0.030
Why?
Ethics Committees, Research
1
2014
41
0.030
Why?
Animals
3
2013
34501
0.030
Why?
Aged, 80 and over
1
2024
7040
0.030
Why?
Research Personnel
1
2014
160
0.030
Why?
Cohort Studies
1
2022
5369
0.020
Why?
Diet, High-Fat
1
2013
238
0.020
Why?
Prospective Studies
1
2022
7043
0.020
Why?
Diet, Reducing
1
2010
84
0.020
Why?
Dietary Carbohydrates
1
2010
152
0.020
Why?
Body Weight
1
2013
931
0.020
Why?
Quality Improvement
1
2017
1100
0.020
Why?
Communication
1
2014
838
0.020
Why?
Phenotype
1
1996
3050
0.020
Why?
Sex Factors
1
2013
1949
0.020
Why?
Energy Intake
1
2010
453
0.020
Why?
Mice, Knockout
1
2013
2752
0.020
Why?
Retrospective Studies
1
2003
14460
0.020
Why?
Dyslipidemias
1
2006
177
0.010
Why?
Munc18 Proteins
1
2003
23
0.010
Why?
SNARE Proteins
1
2003
39
0.010
Why?
Time Factors
1
2013
6503
0.010
Why?
Muscle Fibers, Skeletal
1
2003
190
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2003
937
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2003
756
0.010
Why?
Insulin
1
2010
2318
0.010
Why?
Mice, Transgenic
1
2003
2069
0.010
Why?
Cells, Cultured
1
2003
4008
0.010
Why?
Blood Glucose
1
2003
2092
0.010
Why?
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)